Antigen News and Research

RSS

Presence of protein PARP in tumours may help predict response to chemotherapy

The presence of the protein poly (ADP-ribose) polymerase (PARP) in tumours can help predict their response to chemotherapy, a German scientist will tell the seventh European Breast Cancer Conference (EBCC7) in Barcelona tomorrow (Saturday 27 March). Professor Gunter von Minckwitz, from the German Breast Group Forschungs GmBH, Neu-Isenburg, says that, contrary to current belief that PARP is associated with a limited number of tumours, he and his team found for the first time that PARP expression exists across all breast cancer subtypes, and that such tumours were highly sensitive to chemotherapy.

26 Mar 2010

Pregnancy safe for breast cancer survivors, says study

Women who have been treated for breast cancer can choose to become pregnant and have babies, without fears that pregnancy could put them at higher risk of dying from their cancer, according to a major, new study.

26 Mar 2010

Data on Argos Therapeutics' Phase 2a AGS-004 immunotherapy trial presented at Banff HIV Vaccines meeting

Argos Therapeutics today announced the presentation of data from the Phase 2a trial of AGS-004, providing information on rebound viral genetic diversity in HIV patients treated with the personalized immunotherapy following antiretroviral therapy (ART) interruption. The data were discussed in a poster session at the Keystone Symposia Global Health Series HIV Vaccines meeting, held March 21-26, 2010 in Banff, Canada.

26 Mar 2010

New research may help advance treatment strategies for common liver disease

A research article published in the journal PloS Pathogens could lead to improvements in the production of vaccines for hepatitis A, the most widespread viral disease in the world.

26 Mar 2010

Hybridyne Imaging Technologies – Brookhaven National Lab team vies for top title at 2010 WBT showcase

A team from Hybridyne Imaging Technologies, Inc., and the U.S. Department of Energy's Brookhaven National Laboratory was among over 90 top technology innovators from across the nation and around the world competing in Arlington, Texas, March 16-17, for top honors at the WBT2010 showcase presented by Lockheed Martin.

25 Mar 2010

Tips offered in April 2010 issue of American Journal Of Pathology

A group led by Dr. Massimo Loda at the Dana Farber Cancer Institute, Boston, MA has generated a preclinical model of human prostate cancer that mimics the genetic and growth behavior of primary tumors. Their report can be found in the April 2010 issue of the American Journal of Pathology.

25 Mar 2010

Inhibitex announces net loss of $4.7M for fourth-quarter 2009

Inhibitex, Inc. today announced its financial results for the fourth quarter and year ended December 31, 2009 and provided an update on various corporate developments.

23 Mar 2010

Researchers devise simple water test to check for herbicide clomazone

University of California, Davis, scientists are helping rice farmers in Uruguay stop polluting their waterways -- including drinking-water sources and a globally valuable nature reserve.

23 Mar 2010

New understanding of cell in immune system may guide creation of effective flu vaccines: Study

A new understanding of a certain cell in the immune system may help guide scientists in creating better flu vaccines, report researchers from the Program in Cellular and Molecular Medicine and the Immune Disease Institute at Children's Hospital Boston.

23 Mar 2010

Pevion Biotech commences Phase 1 clinical trial of PEV7 vaccine

Pevion Biotech, the Swiss vaccine company, today announced that PEV7, the first vaccine for chronic recurrent thrush - recurrent vulvovaginal candidiasis has entered Phase 1 clinical trial.

22 Mar 2010

EUREKA project develops unique range of antibodies

EUREKA project E! 3424 RECAN has developed a range of unique and highly specific monoclonal and polyclonal antibodies - the proteins produced in the blood which counteract bacteria, viruses or cancerous cells.

20 Mar 2010

Mini-laboratory: IVD platform to be presented at Analytica trade show

Many illnesses can be reliably diagnosed through laboratory tests, but these in vitro analyses often use up valuable time. A system developed by Fraunhofer research scientists, which can carry out complex analyses on the spot, will soon be ready for the market.

19 Mar 2010

Advaxis publishes new findings on Listeria-derived ActA anti-cancer component

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has published new research findings on ActA as a potential, anti-cancer component and a new complement to the Company’s evolving proprietary Listeria technology platform.

19 Mar 2010

Genocea Biosciences acquires global license for novel Streptococcus pneumoniae antigens from Children’s Hospital Boston

Genocea Biosciences, a vaccine discovery and development company, today announced an exclusive worldwide license for developed countries to a portfolio of Streptococcus pneumoniae antigens from Children’s Hospital Boston. PATH and Genocea retain certain co-exclusive rights to the antigens for use in developing countries under their collaboration agreements with Children's Hospital Boston.

18 Mar 2010

USPTO allows Regulus Therapeutics' claims covering methods of antagonizing miR-181a for regulating immune response

Regulus Therapeutics Inc. announced today that the United States Patent and Trademark Office (USPTO) has allowed claims in U.S. Application Serial No. 11/977,506 covering methods of antagonizing miR-181a to regulate immune response. This patent is owned by Stanford University and licensed exclusively to Regulus. miR-181a has been shown to regulate the response of immune cells, such as T lymphocytes, to specific stimuli and modulation of miR-181a could lead to a novel treatment of inflammatory disease.

18 Mar 2010

OriGene Technologies to build TrueMAB monoclonal antibody collection with $16M Series B financing funds

OriGene Technologies, Inc., a leading gene-centric life sciences company, announced the completion of a $16 million Series B financing led by IDG-Accel, SBI & TH Venture Capital Enterprise, and Zero2IPO. OriGene's previous investors Morningside Venture Investments and President International Development Corp. (PIDC) also participated in this round. The proceeds from the funding will be used to continue to build OriGene's TrueMAB™ monoclonal antibody collection.

18 Mar 2010

Stress during pregnancy may raise infant’s risk to asthma and allergy

Stress during pregnancy may raise the risk of asthma in offspring, according to researchers at Brigham and Women's Hospital and Harvard Medical School in Boston.

18 Mar 2010

Cangene receives European Commission approval to market ImmunoGam

Cangene Corporation today reports that it has received European Commission approval to market Cangene's ImmunoGam(TM) (Human Hepatitis B Immunoglobulin), indicated for immunoprophylaxis of hepatitis B.

18 Mar 2010

ImmunoCellular Therapeutics receives Notice of Allowance covering antibodies targeting pancreatic cancer

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of Allowance from the United States Patent and Trademark Office covering technology relating to monoclonal antibodies that bind to certain epitopes present on pancreatic cancers. This patent will broaden the Company’s proprietary intellectual property for ICT-109 and ICT-37, two of the Company’s monoclonal antibody product candidates.

17 Mar 2010

Meridian Bioscience revises fiscal 2010 guidance, expects net sales between $145M and $153M

Meridian Bioscience, Inc., Cincinnati, Ohio today announced that it is revising downward its previous sales and earnings guidance for the fiscal year ending September 30, 2010. This action is being taken as a result of weaker than expected operating results for the second quarter ending March 31, 2010, based on preliminary results to date. Separately, Meridian announced that it will file a 510(k) for FDA marketing clearance next week in connection with its illumigene™ C. difficile product.

17 Mar 2010

Antigen News and Research

Presence of protein PARP in tumours may help predict response to chemotherapy

Pregnancy safe for breast cancer survivors, says study

Data on Argos Therapeutics' Phase 2a AGS-004 immunotherapy trial presented at Banff HIV Vaccines meeting

New research may help advance treatment strategies for common liver disease

Hybridyne Imaging Technologies – Brookhaven National Lab team vies for top title at 2010 WBT showcase

Tips offered in April 2010 issue of American Journal Of Pathology

Inhibitex announces net loss of $4.7M for fourth-quarter 2009

Researchers devise simple water test to check for herbicide clomazone

New understanding of cell in immune system may guide creation of effective flu vaccines: Study

Pevion Biotech commences Phase 1 clinical trial of PEV7 vaccine

EUREKA project develops unique range of antibodies

Mini-laboratory: IVD platform to be presented at Analytica trade show

Advaxis publishes new findings on Listeria-derived ActA anti-cancer component

Genocea Biosciences acquires global license for novel Streptococcus pneumoniae antigens from Children’s Hospital Boston

USPTO allows Regulus Therapeutics' claims covering methods of antagonizing miR-181a for regulating immune response

OriGene Technologies to build TrueMAB monoclonal antibody collection with $16M Series B financing funds

Stress during pregnancy may raise infant’s risk to asthma and allergy

Cangene receives European Commission approval to market ImmunoGam

ImmunoCellular Therapeutics receives Notice of Allowance covering antibodies targeting pancreatic cancer

Meridian Bioscience revises fiscal 2010 guidance, expects net sales between $145M and $153M

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics